{
  "pmcid": "7837751",
  "sha256": "e504b75db2b85acc341fb49351bdf78cead331b245bc005b0225d1cdd9266dec",
  "timestamp_utc": "2025-11-09T16:15:28.145650+00:00",
  "model_used": "gpt-4o",
  "readability": {
    "flesch_kincaid": 13.44393442622951,
    "reading_ease": 32.10636191677179,
    "word_count": 244
  },
  "consort_scores": {
    "rubric_version": "v3.0-2025-10-14",
    "items": {
      "Title": {
        "score": 1,
        "evidence": "Methods.: This was a randomized, double-blind, placebo-controlled, phase 2 trial of patients undergoing renal transplantation"
      },
      "Trial_Design": {
        "score": 1,
        "evidence": "Subjects were randomized as 2:1 to 3, once-daily IV infusions of ANG-3777, 2 mg/kg (n = 19), or placebo (n = 9)."
      },
      "Participants": {
        "score": 2,
        "evidence": "patients undergoing renal transplantation with <50 cc/h urine output for 8 consecutive hours over the first 24 hours posttransplantation, or creatinine reduction ratio <30% from pretransplantation to 24 hours posttransplantation."
      },
      "Intervention": {
        "score": 2,
        "evidence": "Subjects were randomized as 2:1 to 3, once-daily IV infusions of ANG-3777, 2 mg/kg (n = 19), or placebo (n = 9)."
      },
      "Objective": {
        "score": 0,
        "evidence": "Not reported"
      },
      "Method_Outcome": {
        "score": 2,
        "evidence": "Primary endpoint: time in days to achieve ≥1200 cc urine for 24 hours."
      },
      "Randomisation_Allocation": {
        "score": 0,
        "evidence": "Not reported"
      },
      "Blinding": {
        "score": 3,
        "evidence": "This was a randomized, double-blind, placebo-controlled, phase 2 trial"
      },
      "Number_Randomised": {
        "score": 1,
        "evidence": "Subjects were randomized as 2:1 to 3, once-daily IV infusions of ANG-3777, 2 mg/kg (n = 19), or placebo (n = 9)."
      },
      "Number_Analysed": {
        "score": 0,
        "evidence": "Not reported"
      },
      "Result_Outcome": {
        "score": 2,
        "evidence": "Patients treated with ANG-3777 were more likely to achieve the primary endpoint of 1200 cc urine for 24 hours by 28 days posttransplantation (83.3% versus 50% placebo; log-rank test: χ 2 = 2.799, P = 0.09)."
      },
      "Harms": {
        "score": 1,
        "evidence": "Adverse events occurred in a similar percentage of subjects in both arms."
      },
      "Trial_Registration": {
        "score": 0,
        "evidence": "Not reported"
      },
      "Funding": {
        "score": 0,
        "evidence": "Not reported"
      }
    },
    "total_score": 15,
    "max_score": 25
  }
}